Artificial Intelligence (AI) is playing a crucial role in revolutionizing clinical trials, offering immense opportunities to enhance operational efficiency, reduce timelines, and facilitate precision medicine. Significant benefits are being realized through improved patient enrollment, protocol design, and trial management utilizing Machine Learning (ML), Natural Language Processing (NLP), and predictive analytics. The advancements in AI adoption, regional influences, and technological progress are key drivers behind the gains seen in this field.
The global market for AI in Clinical Trials reached a value of $2 billion in 2024 and is projected to grow substantially from $2.4 billion in 2025 to an estimated $6.5 billion by 2030, reflecting a compound annual growth rate (CAGR) of 22.6% over the period from 2025 to 2030.
A comprehensive analysis of the trends shaping the global AI market in clinical trials is presented in the report. It categorizes the market based on various components, phases, deployment modes, therapeutic areas, and end users while shedding light on emerging trends and potential growth catalysts.
Clinical trials are increasingly leveraging sophisticated algorithms and ML techniques to optimize trial planning, patient recruitment, monitoring activities, and data interpretation. By harnessing AI capabilities, trials are achieving higher efficiency levels, reduced timelines, and greater support for precision medicine through data-driven decision-making in real-time scenarios.
The integration of AI tools in clinical trials is reshaping drug development processes by enabling quicker, more precise decision-making based on data insights at each phase of research. Technologies like ML, NLP, and predictive analytics empower researchers to efficiently identify patients, design protocols, select trial sites, enhance operational efficiency, minimize errors, and expedite the delivery of effective therapies.
The report is rich in content with 56 data tables and 52 additional tables presenting an extensive analysis of the global AI market in pharmaceutical clinical trials. It covers historical revenue data from 2022 to 2024, estimates for 2025, and forecasts for Compound Annual Growth Rates (CAGRs) up to 2030.
Moreover, detailed assessments of market size and revenue growth potential are provided along with a breakdown of market shares based on offerings, deployment models, trial phases, therapeutic areas, end users, and regions. Insights derived from Porter’s Five Forces model and a global supply chain evaluation are included alongside an overview of regulatory frameworks including key international and regional standards governing AI adoption.
The report also delves into recent patent activities highlighting significant granted and published patents while offering an overview of sustainability trends and Environmental Social Governance (ESG) developments emphasizing consumer attitudes as well as ESG practices among industry leaders.
Furthermore, company profiles of major industry players such as IQVIA, Medidata, Saama, Merative, and Nvidia Corp. are featured within the report.